TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03662971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Germinal peptide eye drops
Description: Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
Study: NCT02396797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The new atWork intervention
Description: atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The original atWork intervention
Description: This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
Study: NCT00578058

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling and Sound Therapy
Description: Tinnitus counseling and sound therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling and Sound Therapy
Description: Tinnitus counseling and sound therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling and Sound Therapy
Description: Tinnitus counseling and sound therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling and Sound Therapy
Description: Tinnitus counseling and sound therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling and Sound Therapy
Description: Tinnitus counseling and sound therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Counseling and Sound Therapy
Description: Tinnitus counseling and sound therapy
Study: NCT01158404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900009 - Dose Escalation Phase (Part A)
Description: 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900009 - Dose Confirmation Phase (Part B)
Description: 30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met.
Study: NCT04772430

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: snow globe
Description: Control group; The baby whose height and weight measurements will be taken will be taken to the stretcher, and the vaccine will be administered after the pain score is measured before the procedure. Pain scores will be recorded during and after the procedure.~Experimental group; The baby whose height and weight measurements will be taken will be taken to the stretcher, after the pain score is measured before the procedure, the snow globe will be operated and the vaccine will be applied. The snow globe will continue to work until the application is completed. Pain scores will be recorded during and after the procedure.
Study: NCT01160744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B (ramucirumab)
Description: 10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-1121B (ramucirumab)
Description: 10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6)
Description: Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin (AUC 6)
Description: Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m² on Days 1 and 8 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m² on Days 1 and 8 of every 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin (AUC 5)
Description: Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5)
Description: Day 1 of every 21-day cycle
Study: NCT01535066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Receive acupuncture

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Receive sham acupuncture
Study: NCT04279678

Intervention type: PROCEDURE
Intervention: Mitral valve repair
Description: surgical repair of moderate ischemic mitral regurgitation using pericardial patch or rigid semi-annular ring
Study: NCT02227966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yband (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Yband (YDT-201N)
Description: tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
Study: NCT00726427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose escalation to achieve maximum tolerated dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Oral single dose
Study: NCT01060111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Standard
Description: Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Slow
Description: Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Slow
Description: Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol booster
Description: Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
Study: NCT01004393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide
Description: Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
Study: NCT01997255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
Study: NCT03808454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: strengthening ex, posture training,...

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP+Rehabilitation
Description: combine PRP and Rehabilitation
Study: NCT02965131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary portocaval shunt
Description: The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
Study: NCT04784403

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 PCR and serology tests
Description: Once the informed consent has been signed, the selected subjects must complete an epidemiological survey and go to a UB sample collection center to perform a PCR and serology test for SARS-CoV-2.
Study: NCT04643431

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perflutren
Description: The ultrasound contrast agent is used to improve the quality of ultrasound imaging and is infused over 5-10 minutes. The contrast agent consists of the gas-filled microbubbles smaller than the capillary size which circulate in the vascular system. The contrast agent is cleared from the body naturally within 30 minutes.
Study: NCT03646188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 µg doxorubicin-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 µg doxorubicin-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 µg doxorubicin-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 µg doxorubicin-containing MNA
Description: A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
Study: NCT02642939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
Study: NCT03667300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evogliptin
Description: This group will take daily evogliptin 5mg per oral, not linagliptin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: This group will take daily linagliptin 5mg per oral, not evogliptin
Study: NCT00555425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Buprenorphine/naloxone maintenance (Mtn)
Description: Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Buprenorphine/naloxone detoxification (Dtx)
Description: Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
Study: NCT01262352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet, oral use, twice daily every 12 hours (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet, oral use, twice daily every 12 hours (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, oral use, twice daily every 12 hours (q12h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, oral use, twice daily every 12 hours (q12h)
Study: NCT00645710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Given via hepatic arterial infusion

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: proteomic profiling
Description: Correlative studies
Study: NCT03868566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP-612 dose1
Description: Subjects will take dose1 once a day orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNP-612 dose2
Description: Subjects will take dose2 once a day orally for 12 weeks
Study: NCT00976391

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide + insulin glargine
Description: albiglutide in combination with insulin glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine + preprandial lispro insulin
Description: insulin glargine in combination with preprandial lispro insulin
Study: NCT03115658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 12 week print based intervention
Study: NCT00417729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
Study: NCT03687697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media
Description: A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media
Description: A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media
Description: A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
Study: NCT03631121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basalin to Lantus
Description: continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
Study: NCT00645710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: matrix-assisted laser desorption/ionization time of flight mass spectrometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Correlative studies
Study: NCT01431846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
Study: NCT02975765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: The surgical tip is going to be used to make small cuts into the cortex of the alveolar bone between the crowded teeth.
Study: NCT03861247

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphate-binder intervention
Description: Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate-binder intervention
Description: Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphorus-restricted dietary intervention
Description: Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
Study: NCT01858493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continence promotion group education workshop
Description: Interactive group education workshop promoting continence

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham health lecture
Description: Interactive group education workshop about general health
Study: NCT00645710

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Description: Given IV
Study: NCT04499677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ Ritonavir
Description: Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
Study: NCT00645710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00005940

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC or bone marrow transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03123588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anagrelide
Description: Anagrelide administered orally at a starting dose of 1 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Anagrelide-placebo administered orally BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Ruxolitinib-placebo administered orally BID.
Study: NCT01058005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00002 (natalizumab)
Description: 300 mg intravenous injection every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon beta-1a
Description: 44 mcg subcutaneous injection 3 times per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glatiramer acetate
Description: 20 mg subcutaneous injection once daily